Refine by
Pulmonary Disease Articles & Analysis
94 news found
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. ...
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. ...
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. Speaking about the recent additions to their portfolio of services, Richard James, Executive Vice President and Chief Operating Officer of Vitalograph Clinical Trials says: ...
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. ...
Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, makes breathing difficult for millions of Americans who have been diagnosed with the condition. The Centers for Disease Control and Prevention (CDC) reports that millions more suffer from the respiratory disease, but have not been ...
The addition of deep learning algorithms to VIDA’s LungPrint solution allows the company to improve the performance of lung imaging analysis and enable a more comprehensive assessment of disease probability and progression. This depth of insight empowers physicians to develop personalized treatment plans that can improve outcomes and quality of life. ...
Fluidda’s proprietary in silico platform FRI (Functional Respiratory Imaging) delivers quantitative predictions of regional drug deposition in disease state lungs using Computational Fluid Dynamics (CFD). The FRI platform provides critical information to help understand the availability and activity of the drug at the site of action in the lungs, when complemented by ...
ByFluidda
About Tactile Medical Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. ...
(“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the publication of an expert opinion consensus statement. ...
(“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that management will participate in the William Blair 42nd Annual Growth Stock Conference, which is being held at the Loews Chicago Hotel in Chicago, Il from June 6th-9th. ...
VIDA InsightsTM empowers physicians to better manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease, asthma, emphysema, lung cancer, and COVID-19. ...
Ventilation defect probability mapping (vDPM) is a sophisticated measure of air trapping, relevant in airway diseases such as COPD, asthma, and long COVID1. These functional measures offer valuable insights into the impact of therapy for a variety of lung conditions. ...
The difference is that the specific program of non-invasive ventilation, exercise training, and other interventions prescribed to each patient is based on his or her pulmonary disease phenotype. “Everything is tailored to the needs of the patient,” he explains. ...
ByFluidda
In early April 2022, VIDA received market authorization in Japan for its VIDA Insights software, which is a complementary data-driven solution used by lung care teams at the point of care, aiding them to detect disease early, diagnose with more confidence, make more personalized treatment decisions and use precision lung intelligence to better manage population health. ...
May 1, 2022 – Inhalation therapies, despite their prevalence in treating pulmonary diseases and respiratory-related conditions, have numerous setbacks, such as the deposition of aerosolized particles in the upper ...
Asthma is one of the most common chronic diseases in children. Up to 85% of children with asthma may have type 2 inflammation and are more likely to have higher disease burden. ...
About Eosinophilic Esophagitis (EoE) EoE is a chronic, progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly. ...
“Precision measures like those provided by VIDA Insights, empower care teams to detect disease earlier, diagnose with more confidence, and make more personalized treatment decisions with patients. ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for BCDA-04, a proprietary allogeneic mesenchymal cell (MSC) population that is Neurokinin-1 ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announces the designation of a new reimbursement code for the CardiAMP® Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. ...